Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renstrm E, Seino S, Eliasson L, Rorsman P: GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis
Exp Mol Med
Therefore, successfully launching new muscle-preserving therapies will require extensive market shaping activities to create awareness of unmet need around the risk and implications of muscle loss, to build advocacy for the need to treat, the role of novel pharmacotherapeutic approaches and their clinical, economic and patient-relevant benefits
People living in [a] rural area or [a] community with more social-economic challenges were less likely to be prescribed with this treatment. The class of medications called glucagon-like peptide-1 (GLP-1) agonists are prescribed to treat Type 2 diabetes, a metabolic condition that increases the risk of cardiovascular disease
US$ 27.21
US$ 23.64
US$ 26.26
US$ 27.20
